Gotham Asset Management LLC Sells 16,220 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Gotham Asset Management LLC lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 24.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,502 shares of the company's stock after selling 16,220 shares during the quarter. Gotham Asset Management LLC owned approximately 0.09% of Harmony Biosciences worth $1,738,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HRMY. KBC Group NV boosted its stake in Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after buying an additional 819 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after acquiring an additional 519 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Harmony Biosciences by 34.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock worth $137,000 after acquiring an additional 1,029 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Harmony Biosciences during the 4th quarter valued at approximately $145,000. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Harmony Biosciences by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company's stock valued at $146,000 after purchasing an additional 1,681 shares in the last quarter. Institutional investors own 86.23% of the company's stock.

Harmony Biosciences Trading Down 0.4%

Shares of HRMY stock traded down $0.13 during trading hours on Thursday, reaching $34.37. 208,083 shares of the stock were exchanged, compared to its average volume of 596,663. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 16.30, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The company's 50-day moving average price is $31.59 and its 200-day moving average price is $34.01. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.19. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm's quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 earnings per share. As a group, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. UBS Group reduced their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Finally, Mizuho upped their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research report on Thursday, May 15th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $52.78.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.